Jiwei Huang

Dr. Jiwei Huang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Asian Journal of Surgery
Verified
Journal Article
Open access
ZZZhi-Hong Zhang
Zhi-Hong Zhang
CJChuang Jiang
Chuang Jiang
ZQZe-Yuan Qiang
Ze-Yuan Qiang
YZYi-Fan Zhou
Yi-Fan Zhou
JJJun Ji
Jun Ji
JHJiwei Huang
Jiwei Huang
Hepatectomy is widely considered a potential treatment for hepatocellular carcinoma (HCC). Unfortunately, one-third of HCC patients have tumor recurrence within 2 years after surgery (early recurrence), accounting for more than 60% of all recurrence patients. Early recurrence is associated with a worse prognosis. Previous studies have shown that microvascular invasion (MVI) is one of the key factors for early recurrence and poor prognosis in patients with HCC after surgery. This paper reviews the latest literature and summarizes the predictors of MVI, the correlation between MVI and early recurrence, the identification of suspicious nodules or subclinical lesions, and the treatment strategies for MVI-positive HCC. The aim is to explore the management of patients with MVI-positive HCC.

12 March 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
HLHaotian Liao
Haotian Liao
XCXing Chen
Xing Chen
HWHaichuan Wang
Haichuan Wang
YLYoupei Lin
Youpei Lin
LCLu Chen
Lu Chen
YZYong Zeng
Yong Zeng
Intrahepatic cholangiocarcinoma (iCCA) is the second most prevalent primary liver cancer. Although the genetic characterization of iCCA has led to targeted therapies for treating tumors with FGFR2 alterations and IDH1/2 mutations, only a limited number of patients can benefit from these strategies. Epigenomic profiles have emerged as potential diagnostic and prognostic biomarkers for improving the treatment of cancers. In this study, we conducted whole-genome bisulfite sequencing on 331 iCCAs integrated with genetic, transcriptomic, and proteomic analyses, demonstrating the existence of four DNA methylation subtypes of iCCAs (S1–S4) that exhibited unique postoperative clinical outcomes. The S1 group was an IDH1/2 mutation–specific subtype with moderate survival. The S2 subtype was characterized by the lowest methylation level and the highest mutational burden among the four subtypes and displayed upregulation of a gene-expression pattern associated with cell cycle/DNA replication. The S3 group was distinguished by high interpatient heterogeneity of tumor immunity, a gene-expression pattern associated with carbohydrate metabolism, and an enrichment of KRAS alterations. Patients with the S2 and S3 subtypes had the shortest survival among the four subtypes. Tumors in the S4 subtype, which had the best prognosis, showed global methylation levels comparable to normal controls, increased FGFR2 fusions/BAP1 mutations, and the highest copy-number variant burdens. Further integrative and functional analyses identified GBP4 demethylation, which is highly prevalent in the S2 and S3 groups, as an epigenetic oncogenic factor that regulates iCCA proliferation, migration, and invasion. Together, this study identifies prognostic methylome alterations and epigenetic drivers in iCCA. Significance: Characterization of the DNA methylome of intrahepatic cholangiocarcinoma integrated with genomic, transcriptomic, and proteomic analyses uncovers molecular mechanisms affected by genome-wide DNA methylation alterations, providing a resource for identifying potential therapeutic targets.

18 December 2024 in Cancer Research
Verified
Journal Article
Closed access
SXShuai Xue
Shuai Xue
XCXiangzheng Chen
Xiangzheng Chen
GQGuoteng Qiu
Guoteng Qiu
HLHaotian Liao
Haotian Liao
ZQZeyuan Qiang
Zeyuan Qiang
HWHaichuan Wang
Haichuan Wang
Cdc2-like kinase 1 (CLK1) has dual-specificity kinase ability to phosphorylate tyrosine and serine/threonine protein residues. CLK1 regulates many physiologic processes and has been shown to contribute to multiple types of cancer. In this study, we investigated the functional role of CLK1 during intrahepatic cholangiocarcinoma (ICC) development. The expression of CLK1 was elevated in ICC tumors, and patients with high expression of CLK1 demonstrated poor prognosis. In hydrodynamically transfected mouse models, CLK1 alone was insufficient to induce ICC, whereas CLK1 cooperated with AKT (AKT/CLK1) to trigger ICC initiation. In addition, overexpression of CLK1 in ICC cells facilitated proliferation in vitro and tumor growth in vivo, whereas loss of CLK1 elicited the opposite effects. Moreover, RNA sequencing analysis indicated that high levels of CLK1 corresponded with activation of the Hippo–Yes-associated protein (YAP) signaling pathway. Consistently, AKT/CLK1 murine tumors displayed upregulation of YAP as well as its downstream targets. Furthermore, loss or pharmacologic inhibition of YAP in ICC cells inhibited CLK1-induced growth, and deletion of Yap completely retarded the induction of AKT/CLK1 tumors. Mechanistically, 4D label-free mass spectrometry and coimmunoprecipitation assays revealed WWC2 as a potential mediator of the CLK1–YAP cascade. Collectively, the current findings identify a critical role for CLK1 in promoting ICC development and indicate that inhibiting YAP might be an effective approach for perturbing CLK1-mediated tumorigenesis. Significance: CLK1 drives intrahepatic cholangiocarcinoma initiation and progression by increasing YAP activity, suggesting that targeting YAP could be a potential strategy for treating and preventing CLK1-driven intrahepatic cholangiocarcinoma.

31 December 2024 in BioScience Trends
Verified
Journal Article
Open access
PDF file
SMShizheng Mi
Shizheng Mi
GQGuoteng Qiu
Guoteng Qiu
ZZZhihong Zhang
Zhihong Zhang
ZJZhaoxing Jin
Zhaoxing Jin
QXQingyun Xie
Qingyun Xie
JHJiwei Huang
Jiwei Huang
Lymph node metastasis in intrahepatic cholangiocarcinoma significantly impacts overall survival, emphasizing the need for a predictive model. This study involved patients who underwent curative liver resection between different time periods. Three machine learning models were constructed with a training cohort (2010-2016) and validated with a separate cohort (2019-2023). A total of 170 patients were included in the training set and 101 in the validation cohort. The lymph node status of patients not undergoing lymph node dissection was predicted, followed by survival analysis. Among the models, the support vector machine (SVM) had the best discrimination, with an area under the curve (AUC) of 0.705 for the training set and 0.754 for the validation set, compared to the random forest (AUC: 0.780/0.693) and the logistic regression (AUC: 0.703/0.736). Kaplan-Meier analysis indicated that patients in the positive lymph node group or predicted positive group had significantly worse overall survival (OS: p < 0.001 for both) and disease-free survival (DFS: p < 0.001 for both) compared to negative groups. An online user-friendly calculator based on the SVM model has been developed for practical application.

17 July 2025 in International Journal of Surgery
Verified
Journal Article
Open access
JJJun Ji
Jun Ji
DHDing Hu
Ding Hu
JWJiaao Wang
Jiaao Wang
GQGuoteng Qiu
Guoteng Qiu
HWHaichuan Wang
Haichuan Wang
JHJiwei Huang
Jiwei Huang
Background: Primary hepatic sarcomatoid carcinoma (PHSC) is a rare and aggressive hepatic malignancy characterized by high recurrence rates and poor prognosis. This study aims to evaluate the efficacy of postoperative adjuvant therapy in PHSC patients after surgical resection. Methods: The retrospective study enrolled patients with postoperatively, pathologically confirmed PHSC at a major academic medical center between December 2018 and May 2023. Patients were divided into two groups based on the receipt of postoperative adjuvant therapy. Clinical and follow-up data were retrospectively collected. The primary endpoint was disease-free survival (DFS), and the secondary endpoint was overall survival (OS). Survival curves were generated using the Kaplan–Meier method and compared via the log-rank test. Univariate and multivariate Cox regression analyses were employed to identify prognostic factors. Results: Of 2071 patients with hepatic malignancies, 52 cases (2.5%) were pathologically confirmed as PHSC. The final analysis included 36 PHSC patients, with 19 in the treatment group and 17 in the non-treatment group. The treatment group showed significantly longer DFS compared to the non-treatment group (10.5 vs. 3.0 months, P = 0.008), although the difference in OS was not statistically significant (30.4 vs. 24.1 months, P = 0.229). Multivariable analysis identified adjuvant therapy as an independent protective factor for DFS (HR 0.24, 95% CI 0.08–0.69, P = 0.008). Conclusion: Postoperative adjuvant therapy significantly prolongs DFS in patients with PHSC, although a corresponding OS benefit was not statistically demonstrated. Further multicenter prospective studies are needed to determine the optimal adjuvant therapy regimen for PHSC.

17 December 2023 in Asian Journal of Surgery
Verified
Journal Article
Open access
QXQingyun Xie
Qingyun Xie
GQGuoteng Qiu
Guoteng Qiu
MLMingheng Liao
Mingheng Liao
ZHZiqi Hou
Ziqi Hou
ZJZhaoxing Jin
Zhaoxing Jin
CLChang Liu
Chang Liu
Laparoscopic anatomical hepatectomy guided by near-infrared fluorescence imaging (NIR-FI) has been utilized extensively. However, it is difficult to resect "cone units" above the third branch of the Glissonean pedicle in the right posterior lobe using the laparoscopic positive or negative staining techniques. Therefore, we undertook a new laparoscopic segmentectomy based on the concept of "cone unit" assisted by interventional radiology combined with NIR-FI. Laparoscopic segmentectomy guided by NIR-FI via super-selective hepatic arteriography and trans-arterial injection of ICG was carried out on 13 patients with early-stage HCC between September 2020 and January 2022.11 of cases were successful, and relevant pathological characteristics and perioperative outcomes were retrospectively analyzed. Two cases failed NIR-FI out of which one case involved over-staining to the non-target segment, and in the other case, which was to undergo laparoscopic segment V resection, only the ventral segment was stained while the imaging of the dorsal segment failed. In the intraoperative conditions, the tumor safe margin was 1.1 (0.7-1.55) cm, the interventional operation time was 50 (45.5-60.5) minutes, the operation time was 280 (242.5-307.5) minutes, the blood loss was 100 (50-200) ml, the postoperative hospital stay was 5 (4.5-5.5) days. No cases converted to laparotomy, and no serious postoperative complications developed. NIR-FI through super-selective hepatic arteriography and trans-arterial injection of ICG can provide a clear and lasting navigation aid for laparoscopic segmentectomy, which may have positive implication for early-stage HCC with poor preoperative liver reserves.